Lipodox

Jump to

Sun Pharma Q3 net seen up 25% to Rs 838cr on Taro, Lipodox

Healthcare firm Sun Pharmaceutical is set to announce its third quarter results on Friday. Analysts on an average were expecting profit after tax to grow by 25 percent year-on-year to Rs 838 crore in the quarter, helped by Taro numbers and Lipodox generic.
FDA aapproves generic version of cancer drug Doxil

US health regulators have approved a generic version of the cancer drug Doxil in a move that could ease a months-long shortage that has threatened the lives of thousands of patients.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Lipodox

Sun Pharma Q3 net seen up 25% to Rs 838cr on Taro, Lipodox

FDA aapproves generic version of cancer drug Doxil